TokenPost·
CNS Pharmaceuticals Posts $0.24 Q3 Loss Per Share as Cash Reaches $17.2M

$17.2M
cash on hand
Cash and cash equivalents were $17.2 million at Sept. 30, up from $7.2 million at the end of 2025. The company believes its existing cash can fund planned operations beyond 12 months.